# Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

> **NCT00051558** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 428 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Teriparatide
- **DRUG:** Alendronate Sodium
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00051558
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2006-07
- **Final completion:** 2008-01
- **Target enrollment:** 428 (ACTUAL)
- **Last updated:** 2009-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051558, "Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00051558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*